Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions.

Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.

Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions.

Clin Ther. 1998 Jan-Feb;20(1):2-25; discussion l. Unique Identifier : AIDSLINE MED/98182568
Beach JW; Department of Pharmaceutical and Biomedical Sciences, College of; Pharmacy, University of Georgia, Athens, USA.

Abstract: Since the mid-1980s, four new nucleoside reverse transcriptase RT) inhibitors (zalcitabine, didanosine, stavudine, and lamivudine), two nonnucleoside RT inhibitors (nevirapine and delavirdine), and four new protease inhibitors (saquinavir, ritonavir, indinavir, and nelfinavir) have been approved by the US Food and Drug Administration for the treatment of patients with acquired immunodeficiency syndrome. The driving force behind the development of these new agents has been the increasing need for more potent agents with reduced or modified toxicity profiles. The purpose of this article is to review the absorption, distribution, metabolism, elimination, toxicities, adverse reactions, and mechanism of action of the currently available drugs.

Keywords: *Anti-HIV Agents/THERAPEUTIC USE *HIV Infections/DRUG THERAPY

980730
M9871335

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .